The European Commission announced on 28 July that the new Health Emergency Preparedness and Response Authority (HERA) had signed a Joint Procurement Agreement with the pharmaceutical company GSK for the purchase of Adjupanrix, a prototype fragmented virion, inactivated and adjuvanted vaccine, previously known as the ‘pandemic influenza vaccine’ (H5N1).
The vaccine is indicated for use in adults in the event of an influenza pandemic officially declared by the World Health Organization...